- Universe Pharmaceuticals INC
Universe Pharmaceuticals INC
Website
Traditional Chinese Medicine (“TCM”) is a comprehensive form of healthcare that has been widely adopted in China for more than 23 centuries. TCM rests upon the assumption that the human body is an ecosystem, embodying the fusion of Shen (psyche), Essence (soma), Qi, Moisture (body fluids), and Blood (tissue). Health in the context of TCM is more than just the absence of diseases, but to identify imbalance in human body and restore harmony. TCM is not only intended to cure diseases but to enhance the capacity for fulfillment, happiness and general well-being of people.
We are a pharmaceutical company based in Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (“TCMD”) products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. We have registered and obtained approval for 26 varieties of TCMD products from the National Medical Products Administration (the “NMPA”), and we currently produce 13 varieties of TCMD products, which are sold in approximately 249 cities of 30 provinces in China as of the date of this prospectus. In addition, through our subsidiary Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (“Universe Trade”), we sell not only our own TCMD products, but also biomedical drugs medical instruments, Traditional Chinese Medicine Pieces (“TCMPs”), and dietary supplements manufactured by third-party pharmaceutical companies.
Offering Team
Deal Managers
- Univest Securitie
Lawyers
- Hunter Taubman Fischer & Li LLC
Auditors
- Friedman LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
Deal Tracker
Investors
Filing
10 Mar, 2021Offer
23 Mar, 2021Look Ahead
Lock Up Expiry
23 Sep, 2021Earning
Nov 1, 2018IPO Terms
Offer Price | $5.00 |
Offer Size | 5M |